Editing Systemic scleroderma (section)

===Lung disease===
Active alveolitis is often treated with pulses of [[cyclophosphamide]], often together with a small dose of steroids. The benefit of this intervention is modest.<ref>{{cite journal  |vauthors=Tashkin DP, Elashoff R, Clements PJ, etal |title=Cyclophosphamide versus placebo in scleroderma lung disease |journal=N. Engl. J. Med. |volume=354 |issue=25 |pages=2655–66 |date=June 2006 |pmid=16790698 |doi=10.1056/NEJMoa055120 |doi-access=free }}</ref><ref>{{cite journal  |vauthors=Hoyles RK, Ellis RW, Wellsbury J, etal |title=A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma |journal=Arthritis Rheum. |volume=54 |issue=12 |pages=3962–70 |date=December 2006 |pmid=17133610 |doi=10.1002/art.22204 |doi-access=free }}</ref>

Pulmonary hypertension may be treated with [[epoprostenol]], [[treprostinil]], [[bosentan]], and possibly aerolized iloprost.<ref name=Zandberg/> [[Nintedanib]] was approved for use in the United States [[Food and Drug Administration]] on September 6, 2019, to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated [[interstitial lung disease]] (SSc-ILD).<ref>{{Cite web|url=http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-rare-type-lung-disease|title=FDA approves first treatment for patients with rare type of lung disease|last=Commissioner|first=Office of the|date=2020-02-20|website=FDA|language=en|access-date=2020-02-25}}</ref><ref>{{Cite web |title=FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD |url=https://www.boehringer-ingelheim.com/press-release/fda-approves-nintedanib-ssc-ild |access-date=2022-11-30 |website=www.boehringer-ingelheim.com}}</ref>